CYAD / Celyad: Probably Still Top-Notch In Oncology

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company more_horizontal

Celyad Oncology SA (NASDAQ:CYAD ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sara Zelkovic - Director, Communicat more_horizontal

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo more_horizontal

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) more_horizontal

Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four mon more_horizontal

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biote more_horizontal

Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript more_horizontal

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) more_horizontal